FDA Approves Digital Pill
The agency approved Abilify MyCite, a pill with a sensor that digitally tracks if patients have ingested their medication.
On Nov. 13, 2017, FDA announced it has approved Abilify MyCite (Otsuka Pharmaceutical Co., Ltd.), which is the first drug in the United States that has a digital ingestion tracking system. The pill has an embedded ingestible sensor that records when the medication is taken. Abilify MyCite treats schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder, and is also used as an add-on treatment for depression in adults.
The pill’s sensor sends a message to a wearable patch that transmits information to a mobile application, which allows patients, caregivers, and physicians to track the ingestion of the drug on a smartphone and through a web-based portal. The sensor and patch are made by Proteus Digital Health. Labeling information stresses that it has not been proven if tracking such information improves treatment regimens. Abilify MyCite also contains a boxed warning about the risks of antipsychotic drugs.
“Being able to track ingestion of medications prescribed for mental illness may be useful for some patients,” said Mitchell Mathis, MD, director of the Division of Psychiatry Products in the FDA’s Center for Drug Evaluation and Research, in a press release. “FDA supports the development and use of new technology in prescription drugs and is committed to working with companies to understand how technology might benefit patients and prescribers.”
Source: FDA
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
